Cartesian Therapeutics Inc. (RNAC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER Summary
RNAC Chart
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial
Cartesian Therapeutics Inc. Dividends
Cartesian Therapeutics Inc. Earnings
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
| 8 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
Cartesian Therapeutics Inc. (RNAC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cartesian Therapeutics Inc. ever had a stock split?
Cartesian Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Carsten Brunn Ph.D. CEO | NASDAQ (NMS) Exchange | 816212302 Cusip |
| US Country | 66 Employees | - Last Dividend | 5 Apr 2024 Last Split | - IPO Date |
Overview
Cartesian Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing the field of medicine through its innovative approach in mRNA cell therapies. With a focus on treating various autoimmune diseases, the company stands at the forefront of developing therapies that aim to revolutionize the way such conditions are treated. Cartesian Therapeutics is founded on a commitment to leveraging advanced science to create impactful solutions for patients struggling with autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company embodies a spirit of innovation and a relentless pursuit of excellence in biotechnology.
Products and Services
Cartesian Therapeutics, Inc. has developed a robust pipeline of groundbreaking mRNA cell therapies designed to address a wide range of autoimmune diseases through innovative treatment modalities. Here's an overview of their leading products under development:
- Descartes-08: This cutting-edge product is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy, which is currently in Phase 2b clinical development. It's specifically designed for treating generalized myasthenia gravis and is also being evaluated for its potential in treating patients with systemic lupus erythematosus. Furthermore, Descartes-08 is involved in myeloma autoimmune basket trials, exploring its utility in other autoimmune diseases.
- Descartes-15: Aimed at addressing both autoimmune diseases and myeloma, Descartes-15 represents another significant stride in Cartesian Therapeutics' pursuit of novel treatments. While specific details regarding its mechanism of action and development stage remain concise, Descartes-15 underscores the company's commitment to broadening its impact across multiple autoimmune conditions.
- Descartes-33: This product is currently in preclinical development and showcases Cartesian Therapeutics' ongoing efforts to extend its research and development into new therapeutic areas. Descartes-33 is focused on treating autoimmune diseases, indicating the company's continuous endeavor to innovate and expand its portfolio of solutions for autoimmune disorders.
Contact Information
